Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Investment Securities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gains from Investment Securities for 8 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 1238.19% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 67812.48% increase, with the full-year FY2024 number at $5.0 million, up 1055.6% from a year prior.
  • Gains from Investment Securities was $3.4 million for Q3 2025 at Whitehawk Therapeutics, up from $3.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.6 million in Q2 2021 to a low of -$1.2 million in Q3 2022.
  • A 5-year average of $895914.3 and a median of $69500.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 331.67% in 2024, then surged 1238.19% in 2025.
  • Whitehawk Therapeutics' Gains from Investment Securities stood at $610000.0 in 2021, then skyrocketed by 101.97% to $1.2 million in 2022, then tumbled by 109.74% to -$120000.0 in 2023, then crashed by 331.67% to -$518000.0 in 2024, then surged by 753.6% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Gains from Investment Securities are $3.4 million (Q3 2025), $3.4 million (Q2 2025), and -$114000.0 (Q1 2025).